Meadow Creek Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Meadow Creek Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$266K	Sell	7,260 -66	-0.9%	-$2.61K	0.01%	935
2019 Q2	$341K	Sell	7,326 -1,914	-21%	-$89.9K	0.01%	849
2019 Q1	$371K	Buy	9,240 +286	+3%	+$12.8K	0.01%	799
2018 Q4	$412K	Sell	8,954 -1,826	-17%	-$88K	0.01%	704
2018 Q3	$478K	Buy	10,780 +9,350	+654%	+$429K	0.01%	744
2018 Q2	$56K	Sell	1,430 -12,452	-90%	-$629K	﹤0.01%	1247
2018 Q1	$1M	Buy	13,882 +10,516	+312%	+$772K	0.02%	427
2017 Q4	$222K	Sell	3,366 -2,442	-42%	-$131K	﹤0.01%	960
2017 Q3	$291K	Sell	5,808 -704	-11%	-$33.9K	0.01%	792
2017 Q2	$301K	Sell	6,512 -2,200	-25%	-$80.9K	0.01%	728
2017 Q1	$308K	Hold	8,712	–	–	0.01%	654
2016 Q4	$109K	Buy	+8,712	New	+$104K	﹤0.01%	899

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meadow Creek Investment Management's ESPR Position: Q3 2019 in Review

Meadow Creek Investment Management reduced its Esperion Therapeutics (ESPR) stake by 0.9% in Q3 2019, selling an estimated $2.61K and leaving 7,260 shares worth $266K. The position accounts for 0.01% of the portfolio, ranked #935.

Meadow Creek Investment Management first reported a position in ESPR in Q4 2016 and has held it in 12 quarters since. The position peaked at $1M in Q1 2018. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

Meadow Creek Investment Management held 7,260 shares of Esperion Therapeutics worth $266K as of Q3 2019.
Meadow Creek Investment Management sold 66 Esperion Therapeutics shares in Q3 2019, an estimated $2.61K.
Esperion Therapeutics made up 0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #935 holding.
Meadow Creek Investment Management first reported a position in Esperion Therapeutics in Q4 2016 and has held it in 12 quarters since.
Meadow Creek Investment Management's Esperion Therapeutics position peaked at $1M in Q1 2018.
152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.